Abstract
Cardiovascular diseases are the leading causes of morbidity and mortality in many industrialized societies. Atherosclerosis is the major risk factor for the development of cardiovascular disease based on arterial endothelial dysfunction caused by the impairment of endothelial-dependent dilation. Atherosclerosis is a complex vascular disease resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of a non-redundant role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) may be directly involved in the development of multiple atherogenic mechanisms including advanced oxidative stress, abnormalities in glucose and fat metabolism, and altered energy homeostasis. Recent findings showed that the heteroplasmy level of some somatic mtDNA is associated with coronary atherosclerosis. Although this field should further widely elaborated, heteroplasmic mtDNA mutations could represent a new promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologic conditions. In this review, we critically consider the contribution of mitochondria-related factors to the pathogenesis of the arterial vascular pathology.
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, mitochondrial dysfunction, oxidative stress, cell functions.
Current Pharmaceutical Design
Title:Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Volume: 19 Issue: 33
Author(s): Igor A. Sobenin, Dimitry A. Chistiakov, Yuri V. Bobryshev, Anton Y. Postnov and Alexander N. Orekhov
Affiliation:
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, mitochondrial dysfunction, oxidative stress, cell functions.
Abstract: Cardiovascular diseases are the leading causes of morbidity and mortality in many industrialized societies. Atherosclerosis is the major risk factor for the development of cardiovascular disease based on arterial endothelial dysfunction caused by the impairment of endothelial-dependent dilation. Atherosclerosis is a complex vascular disease resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of a non-redundant role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) may be directly involved in the development of multiple atherogenic mechanisms including advanced oxidative stress, abnormalities in glucose and fat metabolism, and altered energy homeostasis. Recent findings showed that the heteroplasmy level of some somatic mtDNA is associated with coronary atherosclerosis. Although this field should further widely elaborated, heteroplasmic mtDNA mutations could represent a new promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologic conditions. In this review, we critically consider the contribution of mitochondria-related factors to the pathogenesis of the arterial vascular pathology.
Export Options
About this article
Cite this article as:
Sobenin A. Igor, Chistiakov A. Dimitry, Bobryshev V. Yuri, Postnov Y. Anton and Orekhov N. Alexander, Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications, Current Pharmaceutical Design 2013; 19 (33) . https://dx.doi.org/10.2174/1381612811319330013
DOI https://dx.doi.org/10.2174/1381612811319330013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology Diabetes in Menopause: Risks and Management
Current Vascular Pharmacology Cardiovascular Effects of Endogenous Estrogen and Hormone Therapy
Current Vascular Pharmacology Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Editorial (Thematic Issue: “Pregnancy in Women with Metabolic Syndrome”)
Current Pharmaceutical Biotechnology Specific Nutritional Needs for Children. Are Children Small Adults?
Current Nutrition & Food Science Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Current Medicinal Chemistry A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
Current Neuropharmacology Aging and DNA Methylation
Current Chemical Biology Roles of Calcium and Tyrosine Kinases in the Pathogenesis of Type 2 Diabetes Mellitus
Current Enzyme Inhibition Receptor-Based 3D-QSAR Study for Recognizing True Binding Mode of Mercaptoacyldipeptides at the Active Site of Neutral Endopeptidase
Medicinal Chemistry MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology